Expression of EpCAM in uveal melanoma.

Cancer Cell Int 2006 Nov 24;6:26. Epub 2006 Nov 24.

Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, QC, Canada.

Background: Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, and nearly 40% of UM will develop metastasis that will ultimately lead to death. The Epithelial Cell Adhesion Molecule (EpCAM) is a type I transmembrane glycoprotein expressed by carcinomas of head and neck, ovary, colon, breast, kidney and lung. Recently, antibodies against EpCAM such as Edrecolomab and Catumaxomab were developed, and clinical trials with these antibodies have been used in several types of neoplasia. We studied the expression of EpCAM in UM.

Methods: 25 enucleated formalin-fixed, paraffin-embedded UM specimens were immunostained for EpCAM. Histopathological analysis of the specimens with regards to prognostic factors such as cell type, largest (linear) tumor dimension, number of mitotic figures, scleral invasion and tumor infiltrating lymphocytes were done.

Results: None of them was positive for this EpCAM.

Conclusion: In our report, UM did not express EpCAM. Therefore, it is not a helpful immunohistochemical marker to predict the behavior of UM. Further studies are needed to verify if EpCAM could also be related with prognosis and treatment of UM.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1475-2867-6-26DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1676019PMC
November 2006
3 Reads
1 Citation
1.990 Impact Factor

Publication Analysis

Top Keywords

expression epcam
8
uveal melanoma
8
epcam
6
doneresults positive
4
catumaxomab developed
4
edrecolomab catumaxomab
4
epcam edrecolomab
4
positive epcamconclusion
4
developed clinical
4
lymphocytes doneresults
4
types neoplasia
4
antibodies types
4
trials antibodies
4
clinical trials
4
antibodies epcam
4
lung antibodies
4
neck ovary
4
report express
4
dimension number
4
epcam helpful
4

Similar Publications